Ignite Creation Date:
2025-12-24 @ 7:02 PM
Ignite Modification Date:
2025-12-28 @ 10:03 PM
Study NCT ID:
NCT01272557
Status:
UNKNOWN
Last Update Posted:
2014-04-01
First Post:
2011-01-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial
Sponsor:
PD Dr. med. Matthias Dollinger
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-12
Start Date Type:
None
Primary Completion Date:
2014-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2014-12
Completion Date Type:
ESTIMATED
First Submit Date:
2011-01-06
First Submit QC Date:
None
Study First Post Date:
2011-01-07
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-03-31
Last Update Post Date:
2014-04-01
Last Update Post Date Type:
ESTIMATED